Biotheryx Inc. has developed new proteolysis targeting chimeras (PROTACs) comprising a E3 ubiquitin ligase binding moiety covalently bonded to a CDK protein-targeting moiety through a linker.

Voronoi and Voronoi Bio Inc. have patented heteroaryl derivative compounds acting as serine/threonine-protein kinase B-raf (BRAF) inhibitors and reported to be useful for the treatment of cancer.

Phosphatidylinositol 3-kinase α (PI3Kα) (H1047R mutant) inhibitors are described in a Relay Therapeutics Inc. patent as potentially useful for the treatment of cancer, particularly, breast and ovarian cancer.

Merck Sharp & Dohme LLC has patented compounds reported to be useful for the treatment of respiratory syncytial virus (RSV) and metapneumovirus (MPV) infections.

A Genentech Inc. patent discloses new benzothiazole compounds acting as von Hippel-Lindau disease tumor suppressor (VHL) inhibitors and reported to be useful for the treatment of ischemia, cancer and anemia.

Research at Prelude Therapeutics Inc. has led to the development of SMARCA2 and/or SMARCA4 degradation inducers.

Idorsia Pharmaceuticals Ltd. researchers have prepared and tested new thiazoloaryl-methyl substituted cyclic hydrazine-N-carboxamide derivatives acting as orexin OX1 and OX2 receptor antagonists. They are reported to be useful for the treatment of substance abuse and dependence, anxiety, cognitive, sleep, eating and mood disorders.

An F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. patent describes indole derivatives acting as EGFR L858R mutant, T790M/L858R double mutant, T790M/L858R/C797S triple mutant and/or L858R/C797S double mutant allosteric inhibitors reported to be useful for the treatment of non-small-cell lung cancer (NSCLC).

Work at Wake Forest University has led to the development of an H2O2-responsive doxorubicin hybrid codrug able to release H2S (acting as cardioprotective agent). They are reported to be useful for the treatment of cancer.